Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
The aim of the study was to demonstrate the predictive value of the Baseline Prognostic Risk Score (BPRS) in moderate to severe TBI, in a sample of patients treated with neurotrophic factors.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Of the 142 patients enrolled in the CAPTAIN II study, 80 were in the active treatment group.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Five articles (5,685 participants) were included in the current meta-analysis.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
Study scale: Subgroup analyses were performed according to Hunt and Hess grade (good grade ≤ 2, N = 216; poor grade ≥ 3, N = 246) and treatment procedure (clip or coil).
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
The aim of this study was to evaluate the effect of Cerebrolysin in patients with aneurysmal SAH.
Study design
One of the limitations of this study was the retrospective design.
Participants or experimental system
Aneurysmal SAH patients who had their aneurysm obliterated at our institution from 2007 to 2016 were retrospectively studied.
Study scale
Subgroup analyses were performed according to Hunt and Hess grade (good grade ≤ 2, N = 216; poor grade ≥ 3, N = 246) and treatment procedure (clip or coil).
Intervention or exposure
Cerebrolysin was administered at daily doses of 30 ml for at least 3 days.
Comparator
Patients received Cerebrolysin treatment or standard care only (control group).
Outcomes examined
SAH sum score (0–30) was calculated as the mean of the Hijdra score, which is the sum of the amount of blood in ten cistern or fissure points (0–3 each).
Limitations and uncertainty
Further studies are needed to confirm our results.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
The aim of the present study was to examine the age-related modifications of endogenous neurotrophin systems in the brain of male Wistar rats and the effects of CBL on learning and memory as well as the levels neurotrophins and their receptors.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Old (23–24 months) and young (2–3 months) male Wistar rats were used for the study.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
The aim of this trial was to investigate whether stroke patients who receive Cerebrolysin show improved motor function in the upper extremities at day 90 compared with patients who receive a placebo.
Study design
This study was a prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study.
Participants or experimental system
Patients were treated with Cerebrolysin (30 mL/d) or a placebo (saline) once daily for 21 days, beginning at 24 to 72 hours after stroke onset.
Study scale
A total of 208 patients were enrolled in this study between April 2008 and September 2010.
Intervention or exposure
The study medication was administered once daily for 21 days as an intravenous infusion for 20 minutes, beginning at 24 to 72 hours after stroke onset.
Comparator
This prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study compared the effects of 30 mL Cerebrolysin versus placebo during early rehabilitation after stroke.
Outcomes examined
The primary end point was the Action Research Arm Test score on day 90.
Limitations and uncertainty
Because this study was exploratory and had a relatively small sample size, the results should be confirmed in a large-scale, randomized clinical trial.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Study scale: A total of 24 Tau/GSK3β tg mice (3 month (m) old; n = 12 CBL treated and n = 12 saline) and 24 non tg mice (3 m old; n = 12 CBL treated and n = 12 saline) were utilized.
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
For this purpose we sought to investigate the effects of CBL in a tg model of tauopathy.
Study design
Not reported in the declared source.
Participants or experimental system
Accordingly, double tg mice expressing mutant Tau under the mThy-1 promoter and GSK3β (to enhance Tau phosphorylation) were treated with CBL and evaluated neuropathologically.
Study scale
A total of 24 Tau/GSK3β tg mice (3 month (m) old; n = 12 CBL treated and n = 12 saline) and 24 non tg mice (3 m old; n = 12 CBL treated and n = 12 saline) were utilized.
Intervention or exposure
Animals were treated beginning at 3 months of age for 3 months, because at the earlier age group the Tau pathology was subtler, becoming progressively worse at 6 and 12 months of age.
Comparator
By immunoblot, levels of t-Tau were elevated in the Tau/GSK3β bigenic mice compared to the non-tg, no effects of CBL administration on t-Tau were observed (Figure 3A-D).
Outcomes examined
Non-tg and bigenic mice were treated for 3 months (beginning at 3 months of age) with CBL and brains were analyzed with p-tau antibodies.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Background: The aim of our study was to assess the efficacy of Cerebrolysin administration in Broca's aphasics with acute ischemic stroke.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
No summary text is published for this record. This does not change the record’s verification.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Study type: Human research · Verification: Evidence verified by machine against declared source
No summary text is published for this record. This does not change the record’s verification.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Study type: Human research · Verification: Evidence verified by machine against declared source
No summary text is published for this record. This does not change the record’s verification.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Study type: Human research · Verification: Evidence verified by machine against declared source
No summary text is published for this record. This does not change the record’s verification.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Study type: Human research · Verification: Evidence verified by machine against declared source
No summary text is published for this record. This does not change the record’s verification.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.